PetVivo Holdings, Inc. (OTCPK:PETV) Q1 2023 Results Conference Call August 11, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief Financial Officer Conference Call Participants Gary Zwetchkenbaum - Plum Tree Consulting LLC John Dolan Greetings, everyone. And welcome to the PetVivo Holdings First Quarter of Fiscal 2023 Financial Results Conference Call. I am John Dolan, the Chief Busin ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company reported a net loss of $1.97 million and decreased assets, raising substantial doubt about its going concern status [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $5.72 million due to a decline in cash, while stockholders' equity fell to $4.25 million Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | June 30, 2022 | March 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $4,378,668 | $6,106,827 | | Total Current Assets | $5,069,038 | $6,755,400 | | **Total Assets** | **$5,723,557** | **$7,427,332** | | Total Current Liabilities | $1,220,632 | $1,173,486 | | **Total Liabilities** | **$1,471,032** | **$1,440,610** | | **Total Stockholders' Equity** | **$4,252,525** | **$5,986,722** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Revenue grew to $58,174 post-product launch, but surging operating expenses drove a net loss of $1.97 million Statement of Operations Summary (Unaudited) | Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | | :--- | :--- | :--- | | Revenues | $58,174 | $4,145 | | Gross Profit (Loss) | $5,154 | ($906) | | Total Operating Expenses | $1,971,247 | $517,613 | | Operating Loss | ($1,966,093) | ($518,519) | | **Net Loss** | **($1,965,428)** | **($490,629)** | | **Net Loss Per Share** | **($0.20)** | **($0.07)** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations increased significantly to $1.70 million, reducing the company's quarter-end cash balance to $4.38 million Cash Flow Summary (Unaudited) | Activity | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | ($1,701,699) | ($255,861) | | Net Cash Used in Investing Activities | ($24,897) | ($6,063) | | Net Cash (Used in) Provided by Financing Activities | ($1,563) | $381,430 | | **Net (Decrease) Increase in Cash** | **($1,728,159)** | **$119,506** | | **Cash at End of Period** | **$4,378,668** | **$143,084** | [Notes to Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes disclose a going concern warning due to a $65.1 million accumulated deficit, details on stock compensation, and a legal dispute - The company is in the business of licensing and commercializing medical devices and biomaterials for animals, with its headquarters in Minneapolis, Minnesota[24](index=24&type=chunk) - The company incurred a net loss of **$1,965,428** for the quarter and has an accumulated deficit of **$65,091,849** as of June 30, 2022, raising substantial doubt about its ability to continue as a **going concern**[79](index=79&type=chunk) - Total stock-based compensation expense for the three months ended June 30, 2022, was **$231,231**, a significant increase from $55,674 in the same period of 2021[98](index=98&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses revenue growth from its Spryng™ product, rising expenses, and a going concern risk with a seven-month cash runway - The company is an emerging biomedical device company focused on commercializing innovative medical devices for animals, with its lead product being Spryng™ for managing lameness and osteoarthritis in dogs and horses[99](index=99&type=chunk) - On June 17, 2022, the company entered into an exclusive two-year distribution agreement with **MWI Veterinary Supply Co.** to market and sell Spryng™ in the United States[112](index=112&type=chunk) - The company's working capital was **$3,848,406** at June 30, 2022, which management believes is sufficient to fund operations for the next **seven months** but will require additional capital thereafter[126](index=126&type=chunk)[135](index=135&type=chunk) [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Revenue grew to $58,174 from the Spryng™ launch, but higher sales, marketing, and G&A costs widened the net loss to $1.97 million Quarterly Operational Results Comparison | Metric | Q2 2022 | Q2 2021 | | :--- | :--- | :--- | | Revenues | $58,174 | $4,145 | | Sales and Marketing Expenses | $656,569 | $49,731 | | General and Administrative Expenses | $1,243,022 | $330,945 | | Research and Development Expenses | $71,656 | $136,937 | | **Net Loss** | **($1,965,428)** | **($490,629)** | - The increase in net loss was primarily driven by costs to support the launch of Spryng™ and incremental public company costs incurred in the quarter[124](index=124&type=chunk) [Liquidity and Capital Resources](index=22&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $4.38 million in cash and $3.85 million in working capital, sufficient for seven months before requiring new financing - The company closed an underwritten public offering on August 13, 2021, with net proceeds of approximately **$9,781,000**[125](index=125&type=chunk) - As of June 30, 2022, the company had **$4,378,668 in cash** and cash equivalents and **working capital of $3,848,406**[126](index=126&type=chunk) - The company will need to **raise additional capital** in the future to support its efforts to commercialize Spryng™ and fund ongoing operations[127](index=127&type=chunk) [Qualitative and Quantitative Disclosures About Market Risk](index=24&type=section&id=Item%203.%20Qualitative%20and%20Quantitative%20Disclosures%20About%20Market%20Risk) The company is exempt from providing market risk disclosures as it qualifies as a "smaller reporting company" - As a **"smaller reporting company,"** the company is exempt from providing disclosures about market risk[142](index=142&type=chunk) [Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were not effective as of the end of the reporting period - Management concluded that the company's disclosure controls and procedures were **not effective** as of the end of the reporting period[144](index=144&type=chunk) - **No significant changes** were made to internal controls over financial reporting during the first quarter of fiscal year 2023[145](index=145&type=chunk) [PART II. OTHER INFORMATION](index=25&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company is in a legal dispute with its former CTO over an alleged breach of contract, which it believes is without merit - The company has received correspondence from an attorney for Dr. David Masters, former CTO, alleging breach of a settlement and consulting agreement[76](index=76&type=chunk) - The company believes the claims are **without merit** and does not anticipate a material impact on its financial position or results of operations[76](index=76&type=chunk)[147](index=147&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) This report refers investors to the risk factors previously disclosed in the company's Annual Report on Form 10-K - The report refers to the risk factors discussed in the company's **2022 10-K Report**, stating they could materially affect the business[149](index=149&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=25&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity was sold, and the use of proceeds from the August 2021 public offering remains materially unchanged - There were **no unregistered sales** of equity securities in the quarter[150](index=150&type=chunk) - The company completed a Public Offering on August 13, 2021, raising net proceeds of approximately **$9,781,000**[152](index=152&type=chunk) - A portion of the proceeds was used for debt repayment of **$101,400**, with no material change in the intended use of remaining proceeds[153](index=153&type=chunk)[154](index=154&type=chunk) [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists filed exhibits, including a new distribution agreement with MWI Veterinary Supply Co and officer certifications - A **Distribution Services Agreement** dated June 17, 2022, between the company and MWI Veterinary Supply Co, Inc was filed as an exhibit[160](index=160&type=chunk) - Certifications from the Principal Executive Officer and Principal Financial Officer pursuant to **Sarbanes-Oxley Sections 302 and 906** were also filed[160](index=160&type=chunk)

PetVivo Holdings, Inc. (OTCPK:PETV) Q4 2022 Earnings Conference Call June 29, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief Financial Officer Conference Call Participants Gary Zwetchkenbaum - Plum Tree Consulting LLC John Lai John Dolan, can you start the introductions? John Dolan Yes. Thank you, John. Greetings, and welcome to the PetVivo Holdings Fiscal Year Ended March 31, 202 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 000-55167 PetVivo Holdings, Inc. Securities registered under Section 12(g) of the Act: (Exact name of registrant as speci ...

PetVivo Holdings, Inc. (OTCPK:PETV) Q3 2022 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer and President Robert Folkes - Chief Financial Officer Conference Call Participants Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corres ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 000-55167 PetVivo Holdings Inc. (Name of small business issuer in its charter) (State or other jurisdiction of incorporation or or ...

Financial Data and Key Metrics Changes - The company raised approximately $11.25 million through a registered public offering, which closed on August 13, 2021 [5] - As of September 30, the company ended the quarter with over $8.8 million in cash [10] - The most significant event was raising approximately $9.8 million in net proceeds from the registered offering [9] Business Line Data and Key Metrics Changes - The company rebranded its key product for treating osteoarthritis from "Kush" to "Spryng" to avoid associations with cannabis products [5][13] - The company is focusing on expanding sales and marketing efforts to gain veterinary acceptance and generate revenue from Spryng [10] Market Data and Key Metrics Changes - The company plans to attend approximately 19 trade shows, primarily focused on equine products, with the largest show being VMX in Orlando [14] - The company has started launching commercials targeting consumers on major networks such as CNN, MSNBC, and Fox [15] Company Strategy and Development Direction - The company aims to hire six to eight additional salespeople over the next 12 months to enhance its sales force [13] - The strategy includes expanding sales channels through partnerships and conducting additional studies beyond the Colorado state study for both equine and canine markets [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the numbers being within the expected range during roadshows for the offering [20] - The company is focused on educating the market about its product and driving consumer interest through various marketing strategies [15] Other Important Information - Key hires were made to strengthen the management team, including a Chief Operating Officer and a National Director of Sales with extensive veterinary sales experience [6][7] - The company engaged an advertising agency to assist with marketing efforts [11] Q&A Session Summary - No questions were raised during the Q&A session, and management expressed surprise at the lack of inquiries [18][20]

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 000-55167 PetVivo Holdings Inc. (Name of small business issuer in its charter) (State or other jurisdiction of incorporation or organization) 5251 Edina Industrial Blvd. Edina, Minnesota 55439 (Address of principal executive offices) ☒ QUARTERLY REPORT PURSUANT TO SECT ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 000-55167 PetVivo Holdings Inc. (Name of small business issuer in its charter) Nevada 99-0363559 (State or other jurisdiction of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 000-55167 PetVivo Holdings, Inc. (Exact name of registrant as specified in its charter) | | | (State or other jurisdi ...